<qa>  What is the specificity of the 2-SRSD in this population?The assessment schedule is designed to approximate good clinical practice for depression and, thus, may be somewhat less intensive than in some antidepressant trials. The following assessment instruments will be used in this investigation. A two-item, self-report screening tool for depression 2-SRSD taken from the Primary Care Evaluation of Mental Disorders Procedure PRIME-MD screening interview will be used to detect suspected cases of depression among asthma clinic patients. The specificity of the 2-SRSD in this population was 57. Thus, we expect to identify almost all true positives, with a substantial number of false positives. A positive answer to either 1 During the past month, have you often been bothered by feeling down, depressed, or hopeless? or 2 During the past month, have you often been bothered by little interest or pleasure in doing things? will be considered a possible case of depression and qualify for further assessment. MDD is defined as at least five of nine symptoms that must include depressed mood or loss of interest and can also include psychomotor changes, appetite changes or weight loss, sleep changes, decreased concentration, guilt, decreased energy levels lassitude, and suicidal ideation. The symptoms must occur at the same time and last for at least 2 weeks and be associated with a change in functioning. The symptoms must not be the direct physiologic effect of a drug or medical illness e.g., hypothyroidism or bereavement. MDD is diagnosed using a structured clinical interview that addresses each symptom and uses information from the patient, family, physicians, and medical records to establish the diagnosis. 